Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sodium oxybate
Drug ID BADD_D02047
Description Sodium oxybate (Xyrem) is a central nervous system depressant used for the treatment of cataplexy and extreme daytime sleepiness (EDS) associated with narcolepsy. It is the sodium salt of gamma hydroxybutyric acid (GHB) which is an endogenous compound and a metabolite of the neurotransmitter GABA. The exact mechanism of action for treating EDS and cataplexy is not known but is is hypothesised that its therapeutic effects are due to GABA(B) effects on noradrenergic, dopaminaergic and thalamocorticol neurons. The drug follows non-linear pharmacokinetics. As it has been associated with misuse/abuse it is strictly controlled and all patients and prescribers must enroll in the sodium oxybate REMs program in order to gain access to the medication.
Indications and Usage For the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy.
Marketing Status approved
ATC Code N01AX11; N07XX04
DrugBank ID DB09072
KEGG ID D05866
MeSH ID D012978
PubChem ID 23663870
TTD Drug ID Not Available
NDC Product Code 13551-001; 49812-0207; 0054-9628; 69238-2391; 0792-4356; 13551-002; 13551-003; 68727-100; 61960-0221; 13551-004; 59116-5950
UNII 7G33012534
Synonyms Sodium Oxybate | Oxybate, Sodium | Sodium Oxybutyrate | Oxybutyrate, Sodium | Sodium gamma-Hydroxybutyrate | Sodium gamma Hydroxybutyrate | 4-Hydroxybutyrate Sodium | 4 Hydroxybutyrate Sodium | Oxybate Sodium | gamma-Hydroxybutyrate | gamma Hydroxybutyrate | Somsanit | Xyrem
Chemical Information
Molecular Formula C4H7NaO3
CAS Registry Number 502-85-2
SMILES C(CC(=O)[O-])CO.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertonic bladder17.10.01.003; 20.03.03.0030.000858%Not Available
Hypertrichosis23.02.04.0020.000590%
Hyperventilation22.02.01.006; 19.01.02.0040.001127%Not Available
Hypnagogic hallucination19.02.02.0010.000402%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.017033%Not Available
Hypokinesia17.01.02.0090.001046%Not Available
Hypopnoea22.02.01.0210.003353%Not Available
Hypothermia12.05.03.001; 08.05.01.0030.000536%
Hypothyroidism14.11.01.012; 05.02.03.0010.003755%
Impaired gastric emptying07.02.02.0040.001717%
Inappropriate affect19.04.01.0050.002414%Not Available
Incoherent19.10.03.006; 17.02.08.0020.001395%Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.002548%Not Available
Increased appetite14.03.01.003; 08.01.09.0270.003326%Not Available
Influenza like illness08.01.03.0100.003594%
Inguinal hernia07.16.02.0010.000402%Not Available
Initial insomnia19.02.01.005; 17.15.03.0050.020574%Not Available
Insomnia19.02.01.002; 17.15.03.0020.096621%
Insulin resistance05.06.02.003; 14.06.02.0030.000268%Not Available
Intracranial pressure increased17.07.02.0020.000268%Not Available
Iron deficiency14.13.02.0020.000536%Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.0020.000724%Not Available
Irritability19.04.02.013; 08.01.03.0110.017838%
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.002897%Not Available
Keratitis06.04.02.0020.000268%
Ketosis14.01.01.0010.000268%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.049840%
Leukaemia01.10.03.001; 16.01.03.0010.000402%
Libido decreased21.03.02.005; 19.08.03.0010.001314%
Libido increased19.08.03.002; 21.03.02.0070.000912%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 19 Pages